Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
NYSE MKT:CYBN
Holding CYBN?
Track your performance easily
CYBN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.17 - $0.74
Previous Close$0.2
Volume1.86M
Average Volume (3M)5.41M
Market Cap
$1.41M
Enterprise Value-$27.01M
Total Cash (Recent Filing)C$39.00M
Total Debt (Recent Filing)C$366.00K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 11, 2024EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding759,692,495
10 Day Avg. Volume4,983,993
30 Day Avg. Volume5,410,708
Standard Deviation1.16
R-Squared0.10
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)1.25
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.67Price Target Upside1786.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cybin News
PremiumCompany Announcements
Cybin Inc. CEO to Speak at Global Investment Conference
PremiumCompany Announcements
Cybin Inc. Shareholders Approve Key Decisions
PremiumCompany Announcements
Cybin Prepares for Phase 3 Trial of Depression Treatment
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsLead Depression Program on Track for Phase 3 Start; robust Phase 2 data showed significant improvements in depression symptoms, signaling a promising future for CYB003 as an innovative treatment for major depressive disorder.
Safety And EfficacyCYB003 has demonstrated a benign safety profile and remarkable efficacy, achieving a 53.3% response rate and a 20% remission rate versus 0% on placebo, offering hope for a new standard in mental health care.
Strategic PartnershipsPartnership with Fluence to accelerate the rollout of EMBARK, Cybin's psychedelic therapy protocol, could revolutionize treatment delivery and enhance patient outcomes in mental health care.
Bears Say
Dilution RiskRecent equity issuance could dilute existing shareholders' value, potentially leading to a decline in stock price.
External Factors Affecting Clinical TrialsOngoing conflicts, such as the war in Eastern Europe, may disrupt clinical trials, which could delay product development and hurt the stock's performance.
Regulatory And Development RisksStock may be negatively impacted by government regulatory hurdles and the inherent risks of clinical development.
---
Options Prices
Currently, No data available
---
Ownership Overview
6.33% Insiders
0.00% Mutual Funds
38.13% Other Institutional Investors
55.54% Public Companies and Individual Investors
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $0.17 and its highest was $0.74 in the past 12 months.
What is Cybin’s market cap?
Currently, no data Available
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Nov 11, 2024 which is in 53 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Aug 08, 2024. The company reported -$0.015 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.017.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -$0.03.
How many shares outstanding does Cybin have?
Cybin has 759,692,500 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$0.015 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went up 3.846%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
---
Cybin Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (1786.89% Upside)
$3.67 (1786.89% Upside)
Blogger Sentiment
Bullish
CYBN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $228.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.69%
12-Months-Change
Fundamentals
Return on Equity
-49.29%
Trailing 12-Months
Asset Growth
502.45%
Trailing 12-Months
Company Description
Cybin
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
---
CYBN Stock 12 Month Forecast
Average Price Target
$3.67
▲(1786.89% Upside)
Technical Analysis
Best Analysts Covering CYBN
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-39.81%
reiterated a buy rating 27 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -39.81% per trade.
---